A novel approach has been developed to study the reprogramming of protein kinases """"""""en masse"""""""" allowing ~40-60% of the expressed kinome assayed in a single mass spectroscopy run. Our methods utilize Multiplexed Inhibitor Beads (MIBs), consisting of Sepharose beads with covalently immobilized, linker adapted, kinase inhibitors. The technique allows interrogation of kinases known by sequence but which have been understudied due to lack of biologic or phenotypic knowledge or the availability of reagents. MIB/MS identified a kinome response signature to a select MEK1/2 inhibitor AZD6244 that is currently in clinical testing for triple negative breast cancer. The only defined substrate for MEK1/2 are ERK1 and 2, yet we observed changes in activity of kinases in every subfamily of the kinome in response to MEK inhibition. Kinome assessment showed a time-dependent reprogramming that involved an early loss of ERK feedback regulation of RAF and MEK that allowed upstream reactivation of the MEK-ERK pathway. The time dependent change in MIB binding of specific receptor tyrosine kinases (RTKs) such as PDGFR? and DDR1 was readily detected and provided the critical experimental observation that MEK inhibition was driving the expression and activation of multiple RTKs. c-Myc degradation was a key mechanism mediating kinome reprogramming. The fact that multiple RTKs are activated in response to MEK inhibition demonstrates the difficulty in using single kinase inhibitors to arrest tumor progression.
The aims of this proposal include: 1. Define kinome activation state in the human basal/claudin-low like SUM159 cell line and the pre-clinical C3Tag GEMM for basal/claudin-low breast cancer. Kinase signatures will be defined in response to MEK1/2 and PI3K inhibitors alone and in combination, which are currently in clinical testing. 2. Define mechanisms of kinome reprogramming in MEK and PI3K inhibitor resistant tumors and cell lines. 3. Develop rational predictions of kinase inhibitor combinations based on kinome signatures of sensitive and resistant tumors for testing in the C3Tag GEMM for basal/claudin-low breast cancer. The goal is to define combination therapies that overcome resistance and cause apoptosis and tumor regression.

Public Health Relevance

Rationally devising novel kinase inhibitor combination therapies requires detailed knowledge of kinome activity. Currently, there is no discovery mechanism to completely define the dynamic activity of the kinome in response to inhibitors. The MIB/MS technology will be used to assess global kinome behavior and its response to small molecule inhibitors leading to new and effective combination therapies to treat disease.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Research Project (R01)
Project #
Application #
Study Section
Molecular and Integrative Signal Transduction Study Section (MIST)
Program Officer
Dunsmore, Sarah
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Schools of Medicine
Chapel Hill
United States
Zip Code
Tsai, Yihsuan S; Dominguez, Daniel; Gomez, Shawn M et al. (2015) Transcriptome-wide identification and study of cancer-specific splicing events across multiple tumors. Oncotarget 6:6825-39
Stuhlmiller, Timothy J; Miller, Samantha M; Zawistowski, Jon S et al. (2015) Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. Cell Rep 11:390-404
Turowec, Jacob P; Zukowski, Stephanie A; Knight, James D R et al. (2014) An unbiased proteomic screen reveals caspase cleavage is positively and negatively regulated by substrate phosphorylation. Mol Cell Proteomics 13:1184-97
Zawistowski, Jon S; Graves, Lee M; Johnson, Gary L (2014) Assessing adaptation of the cancer kinome in response to targeted therapies. Biochem Soc Trans 42:765-9
Johnson, Gary L; Stuhlmiller, Timothy J; Angus, Steven P et al. (2014) Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer. Clin Cancer Res 20:2516-22
Stinchcombe, Thomas E; Johnson, Gary L (2014) MEK inhibition in non-small cell lung cancer. Lung Cancer 86:121-5
Abell, Amy N; Johnson, Gary L (2014) Implications of Mesenchymal Cells in Cancer Stem Cell Populations: Relevance to EMT. Curr Pathobiol Rep 2:21-26
Stuhlmiller, T J; Earp, H S; Johnson, G L (2014) Adaptive reprogramming of the breast cancer kinome. Clin Pharmacol Ther 95:413-5
Dillon, Patrick J; Gregory, Sean M; Tamburro, Kristen et al. (2013) Tousled-like kinases modulate reactivation of gammaherpesviruses from latency. Cell Host Microbe 13:204-14
Graves, Lee M; Duncan, James S; Whittle, Martin C et al. (2013) The dynamic nature of the kinome. Biochem J 450:1-8

Showing the most recent 10 out of 16 publications